Overactive Bladder Treatment Market Report 2025

The overactive bladder treatment market size has grown steadily in recent years. It will grow from $3.15 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 3.3%. The growth in the historic period can be attributed to medication development, patient awareness, demographic shifts, clinical guidelines, investment in research.

The overactive bladder treatment market size is expected to see strong growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to aging population, advanced therapies, personalized medicine, healthcare investments, patient-centric care. Major trends in the forecast period include non-pharmacological interventions, digital health solutions, alternative medicine acceptance, gender-specific approaches, and holistic care.

The overactive bladder treatment market is poised for growth, driven by the increasing elderly population. With the geriatric demographic, encompassing individuals aged 65 and older, being more susceptible to urinary tract infections due to factors such as diminished urine flow, overactive bladder, enlarged prostate, or kidney stones, there is a heightened demand for treatments targeting overactive bladder symptoms. As reported in July 2022 by ReliefWeb, the global population aged 65 and older is projected to rise from 10% in 2022 to 16% in 2050, reaching 94 million individuals, constituting 23% of the total population by 2050. Thus, the expanding geriatric population is a key factor propelling the overactive bladder treatment market's growth.

The prevalence of bladder cancer is another significant driver for the growth of the overactive bladder treatment market. Bladder cancer, characterized by abnormal cell growth in the bladder, often manifests with symptoms of overactive bladder. Treating these symptoms is crucial for improving the quality of life for individuals with bladder cancer. According to the American Society of Clinical Oncology's estimation in March 2023, around 82,290 adults in the United States are anticipated to be diagnosed with bladder cancer, with approximately 16,710 deaths expected in 2023. This underscores the correlation between bladder cancer and the prevalence of overactive bladder, contributing to the market's growth.

A notable trend in the overactive bladder treatment market is the approval of new products. Leading companies in the market are investing in the development of advanced products that incorporate the latest technologies to maintain their market positions. For example, in April 2023, Avation Medical Inc., a US-based company specializing in advanced neuromodulation and digital health, received FDA clearance for The Vivally System. This non-invasive bladder control therapy device, along with its accompanying mobile application, is designed to treat individuals suffering from urge urinary incontinence and urine urgency linked to overactive bladder syndrome. The system combines an ankle-worn garment with an intelligent controller, delivering personalized neuromodulation energy to the tibial nerve.

Major companies in the overactive bladder (OAB) treatment market are concentrating on developing innovative, cost-effective solutions to lower healthcare expenses and enhance patient adherence. Cost-effective solutions deliver favorable results or achieve their intended objectives at a lower cost than alternatives. For example, in April 2024, Zydus Lifesciences Ltd., an India-based pharmaceutical firm, launched a generic drug for managing OAB, which is characterized by urinary urgency, frequency, and incontinence. This new generic medication, now available in the US market, offers a cost-effective extended-release option. While anticholinergic drugs have traditionally been used to treat OAB, newer therapies are emerging, and the introduction of generics helps reduce healthcare costs and promotes better patient adherence to treatment.

In January 2024, Boston Scientific, a US-based medical technology company, announced its agreement to acquire Axonics Inc. for $3.7 billion. This acquisition enhances Boston Scientific's portfolio in the neuromodulation market, allowing the company to broaden its offerings and improve patient outcomes. By integrating Axonics' advanced technologies, Boston Scientific intends to strengthen its capabilities in delivering comprehensive solutions for patients with urological and gastrointestinal conditions. Axonics Inc., also based in the US, specializes in developing innovative sacral neuromodulation solutions for treating bladder and bowel dysfunction.

Major companies operating in the overactive bladder treatment market include AbbVie Inc., Astellas Pharma Inc., Laborie Medical Technologies Corporation, Endo International plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services Inc., Medtronic plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, Cogentix Medical Inc., Dr. Reddy’s Laboratories Ltd., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Merck & Co. Inc., Macleods Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Novartis International AG, Daiichi Sankyo Company ltd., Boston Scientific Corporation, Grünenthal GmbH, Collegium Pharmaceutical Inc.

North America was the largest region in the overactive bladder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the overactive bladder treatment market report during the forecast period. The regions covered in the overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the overactive bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Overactive bladder encompasses a range of symptoms that can impact a person's frequency of urination and the sense of urgency. Treatment involves modifying specific behaviors, incorporating pelvic floor muscle exercises, and other measures aimed at alleviating symptoms. The objective of treatment is to effectively address the symptoms of an overactive bladder and decrease instances of urgent incontinence.

The primary categories of diseases in the treatment of overactive bladder are idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity involves an involuntary contraction of the bladder muscle, leading to a sudden and urgent urge to urinate. This condition is managed through overactive bladder (OAB) treatment methods, including anticholinergics and beta-3 agonists. Various therapies such as anticholinergics, mirabegron, neurostimulation, intravesical instillation, and other approaches are employed to treat these diseases. These therapies are available through channels such as hospital pharmacies, drug stores, retail pharmacies, and online providers.

The overactive bladder treatment market research report is one of a series of new reports that provides overactive bladder treatment market statistics, including overactive bladder treatment industry global market size, regional shares, competitors with an overactive bladder treatment market share, detailed overactive bladder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the overactive bladder treatment industry. This overactive bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The overactive bladder treatment market consists of revenues earned by entities by providing treatments such as behavioral therapies, nerve stimulation, and percutaneous tibial nerve stimulation (PTNS). The market value includes the value of related goods sold by the service provider or included within the service offering. The overactive bladder treatment market also includes sales of medications used in providing overactive bladder treatment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.